BioChaperone® GLP-1 Amylin
GLP-1 and amylin are two long-acting peptides with complementary mechanisms of action for the treatment of diabetes and obesity.
Direct co-formulation of these two peptides can present major physicochemical compatibility challenges. Due to distinct solubility and stability profiles, there may be no single pH that can simultaneously ensure solubility, colloidal stability, resistance to amyloid fibrillation, and acceptable chemical stability.
BioChaperone® technology makes it possible to overcome these formulation challenges through non-covalent aqueous molecular complexation. Adocia has developed, among other examples, a stable combination of cagrilintide and semaglutide (“CagriSema,” respectively an amylin analogue and a GLP-1 receptor agonist) that is compatible with a multi-use injection pen.
BioChaperone® GLP-1 Amylin offers significant advantages in terms of manufacturing and use:
- Replacement of four auto-injectors for 4 weeks of treatment with a single pen
- Reduced manufacturing costs and increased treatment capacity
- Possibility of personalized dosing